@article {1983,
	title = {The non-genotoxic activator of the p53 pathway Nutlin-3 shifts the balance between E2F7 and E2F1 transcription factors in leukemic cells.},
	journal = {Invest New Drugs},
	volume = {31},
	year = {2013},
	month = {2013 Apr},
	pages = {458-60},
	abstract = {<p>The effect of Nutlin-3, a small molecule inhibitor of the MDM2/p53 interaction, was investigated on the steady-state mRNA levels of the transcription factors E2F1 and E2F7 in a cohort of primary B-chronic lymphocytic leukemia (B-CLL) patient samples (n = 15) and normal peripheral blood mononuclear cells (PBMC). A 24-h treatment with Nutlin-3 significantly down-regulated E2F1 and promoted the concomitant up-regulation of E2F7 in both leukemic and normal cells. Our data suggest that the ability of Nutlin-3 to up-regulate E2F7 likely represents an important molecular determinant in the anti-proliferative activity of Nutlin-3.</p>},
	keywords = {Case-Control Studies, Cells, Cultured, E2F1 Transcription Factor, E2F7 Transcription Factor, Gene Expression Regulation, Leukemic, Humans, Imidazoles, In Situ Hybridization, Fluorescence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukocytes, Mononuclear, Piperazines, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, RNA, Messenger, Tumor Suppressor Protein p53},
	issn = {1573-0646},
	doi = {10.1007/s10637-012-9882-y},
	author = {di Iasio, Maria Grazia and Zauli, Giorgio}
}
